|
| Status |
Public on Dec 19, 2017 |
| Title |
PBMC_Responder_Patient2_6d |
| Sample type |
RNA |
| |
|
| Source name |
peripheral blood
|
| Organism |
Homo sapiens |
| Characteristics |
cell type: peripheral blood mononuclear cell
treatment response: responder
timepoint: 6 days
treatment: Sorafenib
|
| Treatment protocol |
RNA from peripheral blood mononuclear cell of 8 patients at 2 different time points (3 days before and 6 days after Sorafenib treatment) were extractied from 8 ml of blood.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
2ug of total RNA from about 10^7 cells per sample were incubated with DNaseI according the Qiagen manufacture and cleaned up with RNeasy Micro Kit (Qiagen, Hilden, Germany).
|
| Label |
Biotin
|
| Label protocol |
RNA integrity was analyzed by capillary electrophoresis using a Fragment Analyser (Advanced Analytical Technologies, Inc. Ames, IA) and were further processed with the Affymetrix GeneChip Pico kit
|
| |
|
| Hybridization protocol |
Total RNA was hybridized to Affymetrix Clariom S arrays as described by the manufacturers (Affymetrix/Thermo Fisher Scientific, 168 Third Avenue, Waltham, MA USA 02451.)
|
| Scan protocol |
Arrays were washed and stained with GeneChip Fluidics Station 450 and scanned with GeneChip Scanner 3000 using the GeneChip Operating Software (Affymetrix).
|
| Description |
Gene expression data from PBMCs of a responder patient six days after Sorafenib treatment.
|
| Data processing |
R/Bioconductor
|
| |
|
| Submission date |
Mar 07, 2017 |
| Last update date |
Dec 19, 2017 |
| Contact name |
Hauke Busch |
| E-mail(s) |
hauke.busch@uni-luebeck.de
|
| Phone |
+49-451-3101-8470
|
| Organization name |
University of Lübeck
|
| Department |
Lübeck Institute of Experimental Dermatology
|
| Street address |
Ratzeburger Allee 160
|
| City |
Lübeck |
| State/province |
Schleswig-Holstein |
| ZIP/Postal code |
23538 |
| Country |
Germany |
| |
|
| Platform ID |
GPL23159 |
| Series (1) |
| GSE95770 |
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells |
|
